Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 3,720,700 | 3,547,100 | 3,145,000 | 3,434,300 | 3,362,700 |
| Cost of Goods | 491,100 | 480,200 | 433,800 | 517,000 | 436,400 |
| Gross Profit | 3,229,600 | 3,066,900 | 2,711,200 | 2,917,300 | 2,926,300 |
| Operating Expenses | 2,050,200 | 1,997,500 | 1,960,600 | 1,945,400 | 1,815,700 |
| Operating Income | 1,179,500 | 1,069,600 | 751,400 | 972,900 | 1,111,000 |
| Interest Expense | 13,800 | 14,800 | 16,100 | 18,300 | 17,800 |
| Other Income | 327,300 | 573,300 | -34,600 | 193,000 | 17,600 |
| Pre-tax Income | 1,493,000 | 1,628,100 | 700,700 | 1,147,600 | 1,110,800 |
| Income Tax | 152,400 | 195,800 | -21,300 | -12,000 | 103,000 |
| Net Income Continuous | 1,340,600 | 1,432,300 | 722,000 | 1,159,600 | 1,007,800 |
| Net Income | $1,340,600 | $1,432,300 | $722,000 | $1,159,600 | $1,007,800 |
| EPS Basic Total Ops | 12.40 | 13.25 | 6.70 | 10.88 | 9.48 |
| EPS Basic Continuous Ops | 12.40 | 13.25 | 6.70 | 10.89 | 9.48 |
| EPS Diluted Total Ops | 11.54 | 12.41 | 6.27 | 10.21 | 8.89 |
| EPS Diluted Continuous Ops | 11.54 | 12.41 | 6.27 | 10.21 | 8.89 |
| EPS Diluted Before Non-Recurring Items | 11.73 | 10.10 | 7.97 | 10.18 | 10.17 |
| EBITDA(a) | $1,301,200 | $1,190,300 | $865,500 | $1,085,899 | $1,216,400 |